Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
NCT00513695 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
- Lead sponsor
- University of Washington
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- October 16, 2017
- Enrollment
- 68 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
inflammatory breast cancer, male breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer